Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression

European Neuropsychopharmacology

Volumn 19, Issue 6, 2009, Pages 451-456

  Maron, Eduard ^a,b   Tammiste, Anu ^b   Kallassalu, Kristi ^b,c   Eller, Triin ^b   Vasar, Veiko ^b   Nutt, David J ^d   Metspalu, Andres ^b,c  

^a North Estonia Medical Centre   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c UNIVERSITY OF TARTU   (Estonia)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

5 HTTLPR; Escitalopram; Major depression; Pharmacogenetics; Serotonin transporter

Indexed keywords

ESCITALOPRAM; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT RESPONSE;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHI-SQUARE DISTRIBUTION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOTYPE; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 65049084627     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.01.010     Document Type: Article

References (23)

1. Baune B.T., Hohoff C., Mortensen L.S., Deckert J., Arolt V., and Domschke K. Serotonin transporter polymorphism (5-HTTLPR) association with melancholic depression: a female specific effect?. Depress. Anxiety 25 11 (2008) 920-925
2. Hu X.Z., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D., et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 78 5 (2006) 815-826
3. Hu X.Z., Rush A.J., Charney D., Wilson A.F., Sorant A.J., Papanicolaou G.J., et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry 64 7 (2007) 783-792
4. Kato M., and Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry (2008) Nov 4
5. Kennedy S.H., Andersen H.F., and Lam R.W. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J. Psychiatry. Neurosci. 31 2 (2006) 122-131
6. Klein N., Sacher J., Geiss-Granadia T., Mossaheb N., Attarbaschi T., Lanzenberger R., et al. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berl) 191 2 (2007) 333-339
7. Kraft J.B., Slager S.L., McGrath P.J., and Hamilton S.P. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol. Psychiatry 58 5 (2005) 374-381
8. Kraft J.B., Peters E.J., Slager S.L., Jenkins G.D., Reinalda M.S., McGrath P.J., et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol. Psychiatry 61 6 (2007) 734-742
9. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 5292 (1996) 1527-1531
10. Malhotra A.K., Lencz T., Correll C.U., and Kane J.M. Genomics and the future of pharmacotherapy in psychiatry. Int. Rev. Psychiatry 19 5 (2007) 523-530
11. Maron, E., Eller, T., Vasar, V., Nutt, D.J., (in press). Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder. J Clin Psychiatry.
12. Maron E., Lang A., Tasa G., Liivlaid L., Toru I., Must A., et al. Associations between serotonin-related gene polymorphisms and panic disorder. Int. J. Neuropsychopharmacol. 8 2 (2005) 261-266
13. Mrazek D.A., Rush A.J., Biernacka J.M., O'Kane D.J., Cunningham J.M., Wieben E.D., et al. SLC6A4 variation and citalopram response. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2008) Jul 10
14. Murphy Jr. G.M., Hollander S.B., Rodrigues H.E., Kremer C., and Schatzberg A.F. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiatry 61 11 (2004) 1163-1169
15. Perlis R.H., Mischoulon D., Smoller J.W., Wan Y.J., Lamon-Fava S., Lin K.M., et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry 54 9 (2003) 879-883
16. Peters E.J., Slager S.L., McGrath P.J., Knowles J.A., and Hamilton S.P. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry 9 9 (2004) 879-889
17. Popp J., Leucht S., Heres S., and Steimer W. Serotonin transporter polymorphisms and side effects in antidepressant therapy-a pilot study. Pharmacogenomics 7 2 (2006) 159-166
18. Sanchez C., Bogeso K.P., Ebert B., Reines E.H., and Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 174 2 (2004) 163-176
19. Serretti A., Kato M., De Ronchi D., and Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry 12 3 (2007) 247-257
20. Serretti A., Kato M., and Kennedy J.L. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J. 8 2 (2008) 90-100
21. Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., and Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 3 6 (1998) 508-511
22. Smits K., Smits L., Peeters F., Schouten J., Janssen R., Smeets H., et al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. 22 3 (2007) 137-143
23. Vanderkooy J.D., Kennedy S.H., and Bagby R.M. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can. J. Psychiatry 47 (2002) 174-180